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Jeroen Dewulf,1,* and Filip Boyen2,*
Streptococcus suis (S. suis) has often been reported as an important swine pathogen and is considered as a new
emerging zoonotic agent. Consequently, it is important to be informed on its susceptibility to antimicrobial
agents. In the current study, the Minimum Inhibitory Concentration (MIC) population distribution of nine
antimicrobial agents has been determined for nasal S. suis strains, isolated from healthy pigs at the end of the
fattening period from 50 closed or semiclosed pig herds. The aim of the study was to report resistance based on
both clinical breakpoints (clinical resistance percentage) and epidemiological cutoff values (non-wild-type per-
centage). Non-wild-type percentages were high for tetracycline (98%), lincomycin (92%), tilmicosin (72%),
erythromycin (70%), tylosin (66%), and low for florfenicol (0%) and enrofloxacin (0.3%). Clinical resistance
percentages were high for tetracycline (95%), erythromycin (66%), tylosin (66%), and low for florfenicol (0.3%)
and enrofloxacin (0.3%). For tiamulin, for which no clinical breakpoint is available, 57% of the isolates did not
belong to the wild-type population. Clinical resistance and non-wild-type percentages differed substantially for
penicillin. Only 1% of the tested S. suis strains was considered as clinically resistant, whereas 47% of the strains
showed acquired resistance when epidemiological cutoff values were used. In conclusion, MIC values for
penicillin are gradually increasing, compared to previous reports, although pigs infected with strains showing
higher MICs may still respond to treatment with penicillin. The high rate of acquired resistance against tiamulin
has not been reported before. Results from this study clearly demonstrate that the use of different interpretive
criteria contributes to the extent of differences in reported antimicrobial resistance results. The early detection of
small changes in the MIC population distribution of isolates, while clinical failure may not yet be observed,
provides the opportunity to implement appropriate risk management steps.
Introduction
Streptococcus suis (S. suis) is an important swinepathogen affecting pigs of different ages, although sus-
ceptibility to the disease decreases with age after weaning.4,36
It is known to cause meningitis, arthritis, septicemia, en-
docarditis, polyserositis, bronchopneumonia, and abor-
tion,4,23,36 but can also be found in the upper respiratory,
alimentary, and urogenital tract of healthy pigs.4,22 S. suis has
also been implicated in disease in humans, especially among
people in close contact with swine and pork.20,27 Moreover,
S. suis has recently been reported as an emerging zoonotic
pathogen evidenced by a few large-scale outbreaks of severe
S. suis epidemics in Asia.28,41,42
The most frequently applied treatment for pigs with clin-
ical signs of S. suis infection is feed medication with anti-
microbials, particularly, broad-spectrum penicillins.9,19,37
Currently, no effective commercial vaccine is available. Pre-
vention is based on the optimization of management, au-
togenous vaccines, and primarily the strategic administration
of antimicrobial agents at periods with the highest risk, for
example, weaning.21,40 High levels of resistance to tet-
racyclines,25,30 macrolides, and lincosamides30 have been
reported.
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Different methods are often applied for interpreting the
results of antimicrobial susceptibility testing. In most studies,
clinical breakpoints have been used resulting in the catego-
rization of the tested isolates in susceptible, intermediate, or
resistant against the tested antimicrobials (clinical resis-
tance).12 The use of clinical interpretive criteria may be suf-
ficient from the point of view of the clinician as it predicts the
antimicrobial effect of the drug in the patient at the pre-
scribed dose.14,35,38 However, these breakpoints can vary
over time and between countries,24 making comparisons
between different studies and evolution of antimicrobial re-
sistance patterns in S. suis over time hard. Moreover, this
categorization precludes the detection of small changes in the
population distribution that may indicate the acquisition of
new resistance mechanisms of which the clinical implications
are not yet clear, as has been noted for fluoroquinolones and
Gram-negative bacteria.13 For such changes to be noticed,
epidemiological cutoff values are very valuable. These cutoff
values are based on the differentiation between the wild-type
and the non-wild-type population.12,16,24 They enable to de-
tect strains with a decreased susceptibility, which are isolates
with Minimum Inhibitory Concentrations (MICs) that are
non-wild type, but less than or equal to the susceptible
clinical breakpoint.12,35 However, only few studies report
resistance results as MIC population distributions, necessary
for setting the epidemiological cutoff values. Finally, S. suis
from diseased animals have been tested more often29,32,40
than S. suis from clinically healthy animals. This could lead
to biased results, since isolates from diseased animals may
represent a different population3 and since they have often
been exposed to an antimicrobial selection pressure shortly
before sampling.34
This study aimed to report the level of resistance in S. suis
isolates from clinically healthy fattening pigs at slaughter
age. Resistance percentages were calculated based on both
clinical breakpoints and epidemiological cutoff values.
Materials and Methods
Study design, sample, and data collection
For the isolation of S. suis, nasal swabs were taken from
clinically healthy fattening pigs from 50 different pig herds in
Belgium. A list of 140 pig herds that fulfilled the selection
criteria were randomly selected from the Belgian farm-ani-
mal identification and registration database (SANITEL,
2010). The sampling frame consisted of all farrow-to-finish
herds that used a closed or semiclosed production system
and held at least 150 sows and 600 fattening pigs. The sample
was stratified by province (n = 5), proportional to the number
of pig herds per province. A random selection was per-
formed using a computer-generated list (Toolbox, Cameron,
1999). All selected herds were contacted by telephone and
the first 50 herds that were willing to cooperate in the study
were visited between January and October 2010.
The pigs were sampled *2 weeks before the slaughter
age. The average age of the pigs was 182 days (minimum 156
days; maximum 220 days). In each herd, 20 fattening pigs
were randomly sampled.
Bacterial isolation
Swabs were plated on Columbia agar plates with 5% de-
fibrinated sheep blood, supplemented with colistin and na-
lidixic acid (CNA; Oxoid, Basingstoke, United Kingdom)
within 24 hr after collection and cultured at 35C in a 5%
CO2-enriched atmosphere for 24 hr. Colonies showing alpha-
hemolysis were purified for further identification.1,26 Isolates
showing a positive amylase reaction, a negative catalase re-
action, and a negative Vogues-Proskauer test were consid-
ered to be S. suis.1,22,23 The identity of 28 randomly chosen S.
suis isolates was confirmed by sequencing the 16s rRNA gene
as described before.6 S. suis isolates were stored at - 80C
until antimicrobial susceptibility testing.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed on all
isolates using the agar dilution method according to the
standardized methods described by the Clinical and La-
boratory Standards Institute.11
Inocula were prepared suspending colonies in sterile 0.9%
NaCl to a turbidity equivalent of 0.5 Mac Farland and di-
luted 1/10. Using a Steers inoculum applicator, the suspen-
sions were inoculated on the Muller-Hinton II agar (BBL;
Cockeysville, MD) supplemented with 5% sheep blood and
containing doubling concentrations, ranging from 0.03 mg/
ml to 128 mg/ml of the following antimicrobial agents: en-
rofloxacin, erythromycin, florfenicol, lincomycin, penicillin,
tetracycline, tiamulin, tilmicosin, and tylosin. The plates
were incubated at 35C in 5% CO2-enriched atmosphere for
24 hr. The MIC was defined as the lowest concentration
producing no visible growth. S. aureus ATCC29213, En-
terococcus faecalis ATCC29212, and S. pneumoniae
ATCC49619 were included as quality control (QC) strains.
Interpretation of the MIC values was done using both clinical
breakpoints11 and epidemiological interpretative criteria.38
For enrofloxacin, lincomycin, tiamulin, tilmicosin, and tylo-
sin, no clinical breakpoint for S. suis is available.11 For flor-
fenicol and tetracycline, the clinical breakpoint for swine
respiratory disease caused by S. suis was used.11 For eryth-
romycin and penicillin, clinical breakpoints were used, as
described by the Clinical and Laboratory Standards Institute
(CLSI) for veterinary pathogens, but which were based on
CLSI breakpoints for human Streptococci.11 Since no epide-
miological cutoff values are available for S. suis from EU-
CAST,17 acquired resistance was assumed when MIC values
showed a bimodal or multimodal distribution or tailing.8,15
Isolates in the higher range of MICs were considered not to
belong to the wild-type population. For antimicrobials for
which no clear bimodal distribution was present, epidemi-
ological cutoff values were used available from a previous
study carried out in the same laboratory using identical test
conditions. This was done for the following antimicrobials:
penicillin, tilmicosin, erythromycin, lincomycin, tiamulin,
and tetracycline.30 The MIC50 and MIC90 were calculated and
presented the lowest MIC at which at least 50% and 90% of
the isolates in a test population are inhibited, respectively.
Results
In the current study, S. suis was recovered in 33.2% of all
nasal samples (332/1000). The number of isolates obtained
per herd was normally distributed, with on average, 6.6
isolates recovered from one herd (minimum number of
isolates per herd equaled 5 isolates; maximum equaled 8
isolates; median equaled 7 isolates). The MIC values of 10
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antimicrobial agents were determined for 332 S. suis isolates.
Yet, a number of S. suis isolates showed poor growth under
the prescribed conditions, as has been observed before40 and
their MIC could not be determined. Therefore, in this report,
MIC data have been reported for a variable number of
S. suis isolates (Table 1). The MIC values for QC strains were
within the acceptable QC ranges when available.11 For lin-
comycin, QC strains S. aureus ATCC29213 and E. faecalis
ATCC29212 had similar MIC values as described earlier.29,32
In Table 1, the MIC distribution for all tested S. suis iso-
lates is shown. A bimodal distribution was seen for enro-
floxacin. A monomodal distribution was seen for florfenicol.
For penicillin, a distribution with tailing toward higher MIC
values was noted. No clear bimodal distribution was seen for
erythromycin, lincomycin, tylosin, tilmicosin, tiamulin, and
tetracycline.
In Table 2, the clinical breakpoints11 and the epidemio-
logical cutoff values for the different antimicrobials tested are
shown. Based upon clinical breakpoints, percentage of sus-
ceptible, intermediate, and resistant S. suis strains are shown.
Equally, based upon epidemiological cutoff values, % of
wild-type and non-wild-type strains are presented.
No or very low percentages of clinical resistance were
found against florfenicol (0.3%), and penicillin (1%). High to
very high-resistance percentages were observed against
erythromycin (66%) and tetracycline (95%).
Using the epidemiological cutoff values, low percentages
of non-wild-type isolates were seen to enrofloxacin and
florfenicol (0.3% and 0%, respectively). Acquired resistance
was observed for penicillin (percentage of non-wild-type
isolates equals 47%), tiamulin (57%), erythromycin (70%),
tylosin (66–67%), tetracycline (98%), tilmicosin (72%), and
lincomycin (92%).
Discussion
The choice of the epidemiological cutoff value, based on
the distinction between the wild-type and the non-wild-type
population within a bacterial population, should be fixed for
one antimicrobial agent within a bacterial species, indepen-
dent of time. Moreover, given that wild-type MIC distribu-
tions of bacteria of human and animal origin coincide, the
same epidemiological cutoff value can be used for monitor-
ing resistance in humans and in different animals.2 Yet,
discrepancies between antimicrobial susceptibility test pro-
tocols may result in the establishment of a different epide-
miological cutoff value between studies within one bacterial
species for one antimicrobial agent.7,34 Nevertheless, the pre-
ferred method for reporting MIC results is to present all data
in a distribution table, containing the quantitative data39 to
allow the reader to interpret the data with changing inter-
pretive criteria over time (clinically or epidemiologically).
The high percentages of non-wild-type S. suis isolates for
erythromycin, lincomycin, tilmicosin, tylosin, and tetracy-
cline are in accordance with other studies reporting per-
centages of non-wild-type S. suis isolates for macrolides,
lincosamides, and tetracyclines.30,40
Despite differences in interpretive criteria (clinical break-
points or epidemiological cutoff values), susceptibility testing
methods (disk diffusion, microdilution, and agar dilution),
sampled animals (clinically healthy or diseased pigs, sows or
fattening pigs), and geographical location, there seems to be
a similarity concerning results on clinical resistance percent-
ages, when available, and percentages of non-wild-type
S. suis isolates for those antimicrobials, which in some studies
have been supported by the identification of genotypic
resistance mechanisms.30,31
In the farms included in the current study, macrolides
were frequently used during the farrowing and battery pe-
riod.9 Genes encoding cross resistance to pmacrolides, lin-
cosamides, and streptogramin B are widespread among S.
suis isolates.30 As a result, the administration of macrolides
may select for resistance against these antimicrobials.
Similarities between the current study results and others
have equally been found for the low-resistance percentages
against florfenicol40 and enrofloxacin.30,40
For tiamulin, a high percentage of S. suis isolates did not
belong to the wild-type population, defined as having an
MIC of £ 4mg/ml, demonstrating acquired resistance in
these isolates against this antibiotic. For tiamulin, no clinical
breakpoints are available for S. suis and epidemiological
cutoff values do not necessarily predict how a patient will
respond to therapy. However, for 49% of the isolates, the
MIC of tiamulin varied between 32 and > 128mg/ml, being
at least 8 to more than 32 times higher than for isolates be-
longing to the wild-type population. Although it has not yet
been tested, the likelihood that pigs infected with isolates
demonstrating the higher MIC values of tiamulin will
Table 1. Minimum Inhibitory Concentration Distribution for Streptococcus suis Isolates Obtained
from Clinically Healthy Fattening Pigs on 50 Closed or Semiclosed Pig Herds
Antimicrobial
agent Number of strains with MIC (mg/ml)
Number of
isolates tested
£ 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 > 128
Erythromycin 24 40 33 8 6 8 7 16 22 9 7 2 8 136 326
Lincomycin 2 0 3 6 3 9 24 11 10 3 7 7 7 214 306
Tylosin 3 6 1 1 27 63 8 2 3 1 1 4 13 197 330
Tilmicosin 6 0 0 1 2 13 15 20 9 15 9 14 10 174 288
Tiamulin 3 1 5 9 12 25 57 30 10 16 33 34 43 54 332
Tetracycline 0 0 4 2 4 5 9 6 19 40 115 112 14 0 330
Penicillin 22 32 48 71 86 54 13 1 2 0 0 0 0 0 329
Florfenicol 0 0 2 0 11 97 218 2 1 0 0 0 0 0 331
Enrofloxacin 1 9 22 129 122 17 0 0 1 0 0 0 0 0 301
MIC, minimum inhibitory concentration.
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respond well to treatment with this antibiotic should be
considered to be low.34 For evaluation of tiamulin resistance
in S. suis isolates, Zhang et al.43 used the clinical breakpoint
reported by CLSI11 for Actinobacillus spp. causing respiratory
tract disease in pigs (32 mg/ml) and reported that 34.4% of
their isolates were resistant. Although this clinical breakpoint
cannot be extrapolated as such to other bacterial species or
disease conditions,33 the percentage of isolates with a MIC of
‡ 32mg/ml was clearly higher in this study. Also based on
MIC determinations from S. suis isolates recovered between
1999 and 2000 from clinically diseased pigs, carried out in the
same laboratory using identical test conditions,30 a clear shift
toward higher MIC values was observed in this study. The
sampled pigs from this study did not receive tiamulin for
prophylactic or metaphylactic reasons.9 Yet, the use of tia-
mulin as a therapeutic antimicrobial agent against Brachy-
spira spp. and Mycoplasma hyopneumoniae infections is
common18 and cannot be ruled out for this study.
Broad-spectrum penicillins were the most frequently used
antimicrobial class in pigs from this study, as described in a
former study conducted in the same pig herds.9 Based on the
clinical breakpoint for penicillin11 in this study, only one
isolate could be categorized as resistant. Yet, when consid-
ering isolates with MICs beyond the wild-type cutoff value, a
high number of isolates showed a decreased susceptibility.
Penicillin resistance in streptococci is the result of the ac-
quisition of stepwise mutations in genes encoding penicillin
binding proteins.2 A single-point mutation results in isolates
with a modest increase in MIC, and infections due to these
isolates may still be treatable with penicillins, but they are of
great concern as they represent an introductory step to full
resistance.5 Isolates showing higher values of MICs are as-
sociated with additional mutations and most likely lead to
therapy failure.10 Additionally, these mutations are selected
by the use of b-lactam antimicrobials.10 As a result, reporting
a decreased susceptibility based on epidemiological cutoff
values is important as it can act as an early warning for an
emerging clinical problem.2,34
Conclusions
The current study on S. suis isolates from healthy carrier
pigs confirms the high level of acquired resistance to mac-
rolides, lincosamides, and tetracycline. MIC values for pen-
icillin are gradually increasing, compared to previous
reports,30 as has been seen for S. pneumoniae in humans, al-
though pigs infected with strains showing higher MICs may
still respond to treatment with this antibiotic. The high rate
of acquired resistance against tiamulin has not been reported
before.
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